These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20446577)

  • 21. [Anti-diabetic drugs for secondary prevention of cardiovascular disease in mild diabetic and IGT patients: ABC study and PPAR study].
    Asakura M; Kim J; Asanuma H; Kitakaze M
    Nihon Rinsho; 2010 May; 68(5):887-91. PubMed ID: 20446588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperinsulinemia and atherosclerosis.
    Standl E
    Clin Invest Med; 1995 Aug; 18(4):261-6. PubMed ID: 8549011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus.
    Tsai JC; Sheu SH; Chiu HC; Chung FM; Chang DM; Chen MP; Shin SJ; Lee YJ
    Diabetes Metab Res Rev; 2007 Feb; 23(2):111-8. PubMed ID: 16703635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic syndrome is not associated with markers of subclinical atherosclerosis, serum adiponectin and endogenous androgen concentrations in Japanese men with Type 2 diabetes.
    Fukui M; Ose H; Kitagawa Y; Kamiuchi K; Nakayama I; Ohta M; Obayashi H; Yamasaki M; Hasegawa G; Yoshikawa T; Nakamura N
    Diabet Med; 2007 Aug; 24(8):864-71. PubMed ID: 17593243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study.
    Lowe G; Woodward M; Hillis G; Rumley A; Li Q; Harrap S; Marre M; Hamet P; Patel A; Poulter N; Chalmers J
    Diabetes; 2014 Mar; 63(3):1115-23. PubMed ID: 24222348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Vascular wall and diabetes mellitus: what complications and why?].
    Marre M
    Therapie; 1997; 52(5):371-4. PubMed ID: 9501559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome.
    Linnemann B; Voigt W; Nobel W; Janka HU
    Exp Clin Endocrinol Diabetes; 2006 Mar; 114(3):127-34. PubMed ID: 16636979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiologist's role in improving glucose control and global cardiovascular risk in patients with type 2 diabetes mellitus.
    Gotto AM
    Am J Cardiol; 2007 Feb; 99(4A):3B-5B. PubMed ID: 17307053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of diabetes in metabolic syndrome].
    Pelikánova T
    Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning.
    Reaven G
    Circulation; 2005 Nov; 112(20):3030-2. PubMed ID: 16286599
    [No Abstract]   [Full Text] [Related]  

  • 31. [Impaired glucose tolerance (IGT): current understanding and future research directions].
    Terauchi Y; Kadowaki T
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():21-6. PubMed ID: 15779340
    [No Abstract]   [Full Text] [Related]  

  • 32. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.
    Reasner CA
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):136-44. PubMed ID: 18670366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macrovascular and microvascular disease in obese patients with type 2 diabetes attending structured diabetes education program: a population-based propensity-matched cohort analysis of Patient Empowerment Programme (PEP).
    Wong CK; Wong WC; Wan EY; Chan AK; Chan FW; Lam CL
    Endocrine; 2016 Aug; 53(2):412-22. PubMed ID: 26785847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.
    Meigs JB; Rutter MK; Sullivan LM; Fox CS; D'Agostino RB; Wilson PW
    Diabetes Care; 2007 May; 30(5):1219-25. PubMed ID: 17259468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the metabolic syndrome and its components combinations on arterial stiffness in Type 2 diabetic men.
    Levisianou D; Melidonis A; Adamopoulou E; Skopelitis E; Koutsovasilis A; Protopsaltis I; Zairis M; Kougialis S; Skoularigis I; Koukoulis G; Foussas S; Triposkiadis F
    Int Angiol; 2009 Dec; 28(6):490-5. PubMed ID: 20087288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetes and dyslipidaemia.
    Schwartz SL
    Diabetes Obes Metab; 2006 Jul; 8(4):355-64. PubMed ID: 16776742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Macrovascular complications of metabolic syndrome: an early intervention is imperative.
    Tenenbaum A; Motro M; Schwammenthal E; Fisman EZ
    Int J Cardiol; 2004 Nov; 97(2):167-72. PubMed ID: 15458679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance.
    Kendall DM; Harmel AP
    Am J Manag Care; 2002 Dec; 8(20 Suppl):S635-53; quiz S654-7. PubMed ID: 12510788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control.
    Schneider CA
    Curr Med Res Opin; 2006; 22 Suppl 2():S15-26. PubMed ID: 16914072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey.
    ; Bonadonna R; Cucinotta D; Fedele D; Riccardi G; Tiengo A
    Diabetes Care; 2006 Dec; 29(12):2701-7. PubMed ID: 17130208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.